Table 1.
Model | Species | Procedure | Mechanism of Model | Disease Onset | Advantages | Disadvantages | References |
---|---|---|---|---|---|---|---|
MIA | Rat, mouse | Intra-articular injection of MIA | Disrupt chondrocyte glycolysis via inhibiting glyceraldehyde-3-phosphatase dehydrogenase | 1 week | Rapid, reproducible, robust pain-like behaviour and peripheral/central sensitization partially characterized. | Extensive and rapidly developing pathology does not mimic human OA. | [109,110,111,112] |
ACLT | Dog, Rat | Transection of ACL | Surgical destabilization of the knee | 2–3 weeks | Severe OA and subchondral bone destruction, though less rapidly than MIA model. | Technically difficult and time consuming. | [113,114,115] |
DMM | Mouse | Transection of medial menisco-tibial ligament | Surgical destabilization of the knee | 4–8 weeks | Modest OA, less rapidly than ACLT and MIA model. DMM model amenable to genetic manipulation. | Less difficult than ACLT | [107,112,116,117] |
Abbreviation: Monosodium iodoacetate, MIA; Transection of the anterior cruciate ligament, ACLT; Destabilization of medial meniscus, DMM.